Head and neck cancer impacts vital functions; early diagnosis is crucial due to low awareness and varied symptoms. Seek ...

Abbreviations: BS, brainstem injury; CN, cranial nerve injury; NR, not reported; OP, optice nerve or chiasm injury; OS, overall survival; TLN, temporal lobe necrosis. Randomized study; percentage is ...

李振彰博士团队的研究方法使用了深度学习算法，通过训练模型，使其能够从海量内窥镜图像中学习并识别出可能的癌症病变。这一过程不仅提升了早期诊断的准确性，也大大降低了对专业医疗设备的依赖，为基层医疗提供了更加便捷和可及的解决方案。

ALEC-04 is under clinical development by Alentis Therapeutics and currently in Phase II for Nasopharyngeal Cancer.

Local ethic review board (Fujian Cancer Hospital) approved the study (No. K2024-286-01), and patient informed consent was deemed unnecessary, given its retrospective nature. Fig 1. Study profile for ...

Tevimbra is under clinical development by BeiGene and currently in Phase III for Nasopharyngeal Cancer. According to GlobalData, Phase III drugs for Nasopharyngeal Cancer have a 67% phase transition ...

(RDY) said that it has launched Toripalimab in India, the first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma. Toripalimab is a New Biological Entity (NBE).

Nasopharyngeal carcinoma (NPC) is a rare, aggressive form of head and neck cancer that originates in the nasopharynx, the upper part of the throat. The company has launched Toripalimab, a new ...

in India under the brand name Zytorvi for the treatment of adults with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC), a rare form of head and neck cancer. Loqtorzi, a novel anti-PD-1 ...